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Abstract
Background: Insurance coverage of tobacco cessation medications increases their use and reduces smoking prevalence in a
population. However, uncertainty about the impact of this coverage on health care utilization and costs is a barrier to the
broader adoption of this policy, especially by publicly funded state Medicaid insurance programs. Whether a publicly
funded tobacco cessation benefit leads to decreased medical claims for tobacco-related diseases has not been studied. We
examined the experience of Massachusetts, whose Medicaid program adopted comprehensive coverage of tobacco
cessation medications in July 2006. Over 75,000 Medicaid subscribers used the benefit in the first 2.5 years. On the basis of
earlier secondary survey work, it was estimated that smoking prevalence declined among subscribers by 10% during this
period.
Methods and Findings: Using claims data, we compared the probability of hospitalization prior to use of the tobacco
cessation pharmacotherapy benefit with the probability of hospitalization after benefit use among Massachusetts Medicaid
beneficiaries, adjusting for demographics, comorbidities, seasonality, influenza cases, and the implementation of the
statewide smoke-free air law using generalized estimating equations. Statistically significant annualized declines of 46%
(95% confidence interval 2%–70%) and 49% (95% confidence interval 6%–72%) were observed in hospital admissions for
acute myocardial infarction and other acute coronary heart disease diagnoses, respectively. There were no significant
decreases in hospitalizations rates for respiratory diagnoses or seven other diagnostic groups evaluated.
Conclusions: Among Massachusetts Medicaid subscribers, use of a comprehensive tobacco cessation pharmacotherapy
benefit was associated with a significant decrease in claims for hospitalizations for acute myocardial infarction and acute
coronary heart disease, but no significant change in hospital claims for other diagnoses. For low-income smokers, removing
the barriers to the use of smoking cessation pharmacotherapy has the potential to decrease short-term utilization of
hospital services.
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Cigarette smoking is the leading preventable cause of death in
the United States. It also contributes to health disparities, as
tobacco use is highest in individuals with less education and lower
incomes. In the short term, the only way to decrease tobacco use
rates is to increase population-wide smoking cessation rates [1,2].
This decrease can be achieved by encouraging more smokers to
try to quit and/or by increasing the success of those quit attempts
with effective treatment, which includes counseling and/or
pharmacotherapy with nicotine replacement products, bupropion,
or varenicline [2,3].
At the population level, smoking cessation attempts and quit
rates can be increased by reducing the cost of treatment to the
smoker [3–5]. Smoking cessation treatment is not well covered in
current health insurance programs, especially in state Medicaid
programs that cover low-income individuals, who are more likely
to be smokers. Currently, only 45% of state Medicaid programs
offer tobacco cessation treatment that includes both pharmaco-
therapy and counseling, but only 12% cover behavioral counseling
and all medications approved for tobacco cessation treatment by
the US Food and Drug Administration (FDA) [6].
A barrier to the adoption of comprehensive tobacco treatment
coverage, especially by publicly funded health insurance programs
is the projected impact on health care costs. The health care costs
of smokers who quit decline within 2 to 5 y after quitting [7–10],
but the delay in cost recovery has been a barrier to governments
considering adoption of smoking cessation benefits. Without better
evidence of health improvements or cost containment, it is difficult
for policy makers to mandate benefits that will incur significant
expenses, especially in light of return-on-investment (ROI) models
that show short term increases in health care costs following
tobacco cessation. To date, to our knowledge, no US state has
examined the impact of a publicly funded tobacco cessation
benefit on medical claims for tobacco-related diagnoses.
In 2006, as part of a comprehensive health care reform law,
Massachusetts mandated tobacco cessation treatment for all
subscribers aged 18 y and older who were insured through
MassHealth, the state’s Medicaid program. Prior to this law,
MassHealth did not provide tobacco cessation benefits to its
subscribers. Starting July 1, 2006, the tobacco cessation benefit
provided comprehensive coverage for both pharmacotherapy and
counseling with minimal copay. On the basis of secondary surveys
from the Behavioral Risk Factor Surveillance System (BRFSS), it
was estimated that nearly 40% of smokers on MassHealth used the
benefit to obtain either prescription or over-the-counter medica-
tions to help them quit [5]. In the first 2.5 y after this low-barrier
insurance coverage was offered for tobacco cessation medications,
a significant drop in smoking prevalence was observed among the
Massachusetts Medicaid population [5]. Using BRFSS survey
responses, smoking prevalence in the prebenefit period was
estimated to be 38.3%. The rate dropped to 28.8% 2.5 y later.
Moreover, a joinpoint analysis indicated that the drop in
prevalence coincided with the implementation date of the
MassHealth tobacco cessation benefit. BRFSS data for this period
also showed no change in the percentage of smokers making quit
attempts (1 d or longer). However, there was a significant increase
in the percentage of former smokers reporting recent quit success.
Specifically, the percentage of smokers reporting that they quit
smoking in the previous 12 mo rose from 6.6% in the prebenefit
period to 19.1% in the postbenefit period. Taken together, these
findings suggest that a tobacco cessation benefit with low barriers
can significantly reduce smoking prevalence in a Medicaid
population.
The present study analyzes MassHealth claims data to explore
the effect of comprehensive coverage of smoking cessation
treatment on MassHealth subscribers’ use of hospital care, which
is a major contributor to overall health care costs [11,12]. Because
these claims data do not include information about the smoking
status of individuals using health services, we could not compare
the claims experience of individuals by smoking status over time.
Instead, we compared MassHealth subscribers’ rates of hospital-
ization for specific diagnoses as a function of time before and after
use of the tobacco cessation pharmacotherapy benefit, controlling
for trends in hospital care utilization.
We hypothesized that a subscriber’s probability of hospitaliza-
tion for tobacco-related diagnoses would decrease as a function of
time after use of the tobacco cessation benefit when compared to
the same individual’s probability of hospitalization prior to the
benefit use. We further hypothesized that this postutilization
reversal of risk would vary by diagnosis. Tobacco-related
diagnoses with more rapid risk reductions would likely show
significant reductions in probability of hospitalization, while those
diagnoses with longer term risk reductions would not.
Method
Study Design
We conducted a longitudinal analysis comparing MassHealth
subscribers’ rates of hospitalization for specific diagnoses before
and after their first use of the tobacco cessation pharmacotherapy
benefit, controlling for trends in hospital care utilization.
MassHealth and the Massachusetts Department of Public Health
(MDPH) operate under the umbrella of the Massachusetts
Executive Office of Health and Human Services (EOHHS). All
EOHHS employees are required to be trained regarding ethics,
confidentiality, and privacy issues related to the use and
dissemination of health data. A data sharing agreement for this
project was prepared by MassHealth and signed by representatives
of MassHealth and MDPH. This agreement required that all
claims records be stored on a secure password-protected server.
Access to the claims records was limited to four of the authors on
this paper (TL, MP, LW, and LK).
Tobacco Cessation Benefit
The tobacco cessation benefit, which began on July 1, 2006,
provided coverage for both pharmacotherapy and counseling.
With a doctor’s prescription, MassHealth subscribers could obtain
FDA-approved smoking cessation pharmacotherapies for US$1–
US$3 for a 1-mo supply including over-the-counter medications.
No preauthorization was required for the nicotine patch, gum, or
lozenge, bupropion, or varenicline. Smokers could obtain a 90-d
supply up to twice per year. In-person smoking cessation
counseling services were also covered by the benefit. The state
already provided up to five sessions of free telephone counseling
through the state’s quitline; this continued unchanged with the
new cessation benefit. The counseling services were not required
in order for subscribers to get pharmacotherapy.
Population
The population consisted of MassHealth subscribers who used
the tobacco cessation pharmacotherapy benefit. The analysis was
limited to use of the pharmacotherapy benefit, because use of the
counseling benefit was very low compared to use of the
pharmacotherapy benefit; 97% of all claims were pharmacother-
apy claims. Since 2006, this percentage has varied less than 1%
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had at least one claim for a tobacco cessation medication.
Use of the benefit was defined as having a claim for a
prescription of an FDA-approved tobacco cessation medication
(any nicotine replacement product or varenicline). Subscribers
who had a claim for a bupropion prescription were excluded from
the analysis because the drug is not prescribed only for smoking
cessation. To be included in the analysis, recipients were required
to have a prescription for a tobacco cessation medication filled
between July 1, 2006 and November 17, 2007. The end date was
chosen to allow for a minimum of 6 mo of postutilization claims.
In addition, recipients had to have at least 321 d of MassHealth
eligibility in the 365 d both prior to and after the use of the benefit,
excluding days where the recipient was dually eligible for
Medicare and Medicaid, and had to be MassHealth eligible for
at least 51 d in each 8-wk time segment, excluding days where the
recipient was dually eligible for Medicare and Medicaid.
Data
MassHealth prepared raw eligibility and claims files for all
subscribers who used the tobacco cessation benefit prior to
November 17, 2007. Claims were included from all three types of
MassHealth plans: fee for service (FFS), primary care clinician
(PCC), and managed care organization (MCO). Full claims data
were available for each plan, including the MCO that operates
under a prospective payment scheme. The records included claims
for inpatient hospitalizations (e.g., hospital specific charges),
outpatient events (e.g., emergency department charges), physician
services, medical services (e.g., hospice, physical therapy), and
pharmacy prescriptions. All data records included a claim date or
a specific date of service. All records except pharmacy claims
included up to five International Classification of Diseases, 9th
edition Clinical Modification (ICD 9) diagnosis codes.
Data for individual recipients were organized to produce a type
of health history. Each history was broken into 33 consecutive 8-
wk segments that were designed so that the implementation date of
the tobacco cessation benefit (July 1, 2006) was the start of one of
the 8-wk segments. The first segment began on August 2, 2003,
and the implementation date of the MassHealth tobacco cessation
benefit occurred at the start of the twentieth segment.
Outcomes
The outcomes of interest were claims for inpatient hospitaliza-
tion with specific diagnoses during a given time segment. Only
primary diagnoses were used. Diagnosis groups were defined
according to the Healthcare Cost and Utilization Project (HCUP)
clinical classification system [13]. With the exception of pregnancy
or birth-related hospitalizations, all diagnosis groups with at least
200 hospitalizations were evaluated for changes in the likelihood of
hospitalization comparing hospitalization rates prior to and
following the first utilization date for tobacco cessation medication.
Fifteen diagnosis groups had at least 200 hospitalizations in the
time frame studied. Four of the 15 diagnostic groups were related
to cardiovascular disease (CVD). Four were respiratory conditions.
The remaining seven spanned a variety of conditions that were
either known not to be related to tobacco use or were smoking-
related but had a risk that would not go down in the short term
following smoking cessation (Table 1). Hospitalizations for cancer
diagnoses were rare and therefore not evaluated.
Inpatient hospitalization events were recorded in the following
manner. For each individual, any 8-wk segment that included an
inpatient hospital admission for a specific HCUP diagnosis group
was given a value of 1. All time segments for an individual that did
not include an inpatient hospital admission for a specific HCUP
diagnosis group were assigned a value of 0. Multiple unique
admissions in a single time segment were counted only once. For
all analyses, the outcome measure was whether or not a
hospitalization occurred in a given time segment. The vast
majority of periods with recorded hospitalizations included only
one inpatient admission per individual for a given period. For
schizophrenia and other psychotic disorders, 19% of periods with
admissions had more than one admission in that period; this was
the maximum value for all diagnostic groups studied. The
minimum level for multiple admissions was found for diagnoses
of biliary tract disease with 3% multiple admissions. The
remainder of diagnostic groups evaluated had approximately
Table 1. Diagnostic group codes evaluated.
Diagnostic Group Codes Clinical Group Description Based on HCUP Classifications
Cardiovascular group codes AMI (HCUP =100)
Coronary atherosclerosis and other heart disease (HCUP =101)
Nonspecific chest pain (HCUP =102)
Congestive heart failure (HCUP =108)
Respiratory group codes Pneumonia except by TB or STD (HCUP =122)
COPD and bronchiectasis (HCUP =127)
Asthma (HCUP =128)
Respiratory failure insufficiency arrest (HCUP =131)
Other conditions Diabetes mellitus with complications (HCUP =50)
Biliary tract disease (HCUP =149)
Pancreatic disorders not diabetes (HCUP =152)
Skin and subcutaneous skin infections (HCUP =197)
Abdominal pain (HCUP =251)
Mood disorders (HCUP =657)
Schizophrenia and other psychotic disorders (HCUP =659)
STD, sexually transmitted disease; TB, tuberculosis.
doi:10.1371/journal.pmed.1000375.t001
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admissions.
The 8-wk time segment that included the first use of tobacco
cessation medications was excluded from all analyses because
smoking cessation attempts are often associated in time with
adverse health events. Developing new symptoms or receiving
treatment for tobacco-related disease can stimulate a smoker to
attempt to quit. Standards for hospital quality developed by the
Joint Commission assess provision of smoking cessation advice for
smokers hospitalized for acute myocardial infarction (AMI), heart
failure, and pneumonia [14]. Including the time segment when
treatment began in the model would have overestimated the
impact of tobacco cessation treatment.
Independent Variables
Basic demographic data were ascertained from the eligibility
file, including gender, age, race/ethnicity, and English-speaking.
We also accounted for comorbid medical diagnoses using two
methods. First, each segment was scored for health risk during the
previous 336 d (six segments) using the Chronic Illness Disability
Payment System (CDPS) [15]. CDPS was developed using
diagnoses recorded on Medicaid claims records. It has been used
to assess health status and to estimate future payments for
individual Medicaid subscribers. Also, the HCUP clinical
classification system was used to score health risk. All primary
and secondary diagnoses were included. The earliest diagnosis
date was recorded for nine HCUP categories: AMI, asthma,
congestive heart failure, chronic obstructive pulmonary disease
(COPD), diabetes, gastritis and duodenitis, hypertension, lupus or
other connective tissue disease, and cerebrovascular disease. Those
time segments in the patient health history that predated the
diagnosis were assigned a value of 0. Those time segments after
and including the diagnosis date were assigned a value of 1.
Similar coding was undertaken for previous use of medications for
treating hypertension and/or hyperlipidemia.
Given the relationship between influenza cases and coronary
heart disease (CHD) [16], we also included weekly counts of
‘‘influenza-like cases’’ as recorded by the Massachusetts Depart-
ment of Public Health. Finally, since research has shown that
smoke-free air laws reduce smoking-related health events espe-
cially cardiovascular events, we included an indicator for time
segments after the implementation of the Massachusetts Smoke-
Free Workplace Law (effective date July 5, 2004).
Analytic Model
Data were analyzed using generalized estimating equations
(GEEs) using a logistic link with hospitalization in each time
segment as the dependent variable. Generally, we estimated a
trend in hospitalization rates prior to benefit utilization and a
change in that trend following use of the tobacco cessation benefit.
Our primary goal was estimating the magnitude of this change in
trend. The general trend was characterized as time in years since
August 2, 2003. The change in trend was recorded as the time in
years since a recipient’s first use of the tobacco cessation benefit.
Our primary goal is estimating the magnitude of this change in
trend. Start of tobacco cessation treatment was recorded as the
earliest time segment in which an FDA-approved tobacco
cessation medication prescription was filled. Because many
cardiovascular and respiratory conditions have a seasonal quality,
annual and semi-annual sine and cosine terms were also included
in the model [17]. We adjusted for correlation within individuals
across time, assuming a first-order autoregressive structure. All
analyses were conducted using SAS 9.1, PROC GENMOD (SAS
Corporation).
Results
Between July 1, 2006, and May 9, 2009, 74,454 MassHealth
individual subscribers used the pharmacotherapy benefit. After
applying the exclusion criteria described above, 21,656 were
eligible for analysis. 35,765 of the original 74,454 individuals were
excluded because they first used the benefit after November, 16,
2007, and completeness of claims data for the postutilization time
period for these individuals could not be assured. 18,389
individuals were excluded because these subscribers had insuffi-
cient eligibility in the year before first utilizing tobacco cessation
medications, insufficient eligibility in the year after first use of
tobacco cessation medications, or were dually eligible for
Medicare. The average case included in the analysis had claims
covering 27.5 8-wk segments with an average of 8.7 segments in
the postutilization time period.
Table 2 shows demographic and other comparisons for those
individuals included in the analysis and those excluded. In general,
individuals included were slightly older and more likely to be
female, white, and non-English speaking.
Among the 21,656 benefit users in the sample, 8,194 (37.8%)
had at least one inpatient hospitalization during the study period.
In total, there were 17,084 uniquely dated inpatient hospitaliza-
Table 2. Comparison of benefit users included in analysis to those excluded from analysis.
Benefit User Characteristics Included (n=21,656) Excluded (n=52,798)
First use of tobacco cessation medications between 7/1/2006–11/16/2007 7/1/2006–5/9/2009
Average age (y) 42.1 41.1
Percent male 30.9 43.9
Percent race/ethnicity = white non-Hispanic 71.8 55.9
Percent race/ethnicity = Black non-Hispanic 7.0 5.4
Percent race/ethnicity = Hispanic 5.2 6.0
Percent race/ethnicity = not listed 15.5 31.5
Percent English spoken 73.2 86.4
Percent days eligible for MassHealth (no dual eligible days included) 90.2 46.9
Percent days not eligible for MassHealth 8.4 34.8
Percent days dually eligible for MassHealth and Medicare 1.4 18.3
doi:10.1371/journal.pmed.1000375.t002
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occurred in the prebenefit period. The most common primary
diagnosis group was asthma, followed by COPD and pneumonia.
Unadjusted rates of hospitalization were calculated prior to
accounting for seasonality, influenza, demographics, previous
health risks, and smoke-free air laws. Overall, there was a 7%
(95% confidence interval [CI] 3%–10%) annualized increase in
the unadjusted rate of hospital admissions from the pre-utilization
period to the postutilization period (Table 3). There were also
increases in the annualized unadjusted rates of hospital admissions
for all primary diagnoses of respiratory conditions, congestive
heart failure, abdominal pain, and mood disorders. There was a
significant decrease in the annualized unadjusted rate of hospital
admissions for a primary diagnosis of coronary atherosclerosis (see
Table 3).
Following adjustments for demographics, prior health risks,
seasonality, statewide influenza rates, and the implementation date
of the Massachusetts Smoke-Free Workplace Law, trend changes
in likelihood of hospitalization during the postutilization period
were found for AMI and atherosclerosis. Because hospitalizations
are relatively rare in our population (19% annual risk of
hospitalization), we interpret our odds ratios as changes in the
likelihood of hospitalization. For AMI, there was a 46%
annualized decrease (95% CI 2%–70%). For coronary athero-
sclerosis, the annualized decreased was 49% (95% CI 6%–72%).
Likelihood of hospitalization for nonspecific chest pain was lower
but this change did not reach significance. No other diagnosis
group showed a significant increase or decrease in likelihood of
hospitalization in the postutilization period.
Quadratic terms were added to all models to test for
nonlinearity in the postutilization period. No diagnosis group
showed any significant nonlinearity.
Discussion
Here we extended previous research in smoking prevalence
among MassHealth beneficiaries by examining claims data to
explore whether the utilization of a low-barrier benefit for tobacco
Table 3. Number of admissions by group, unadjusted change in hospital admissions in pre-utilization period compared to
postutilization period with p-value and 95% CI, annualized change in inpatient hospital admissions postutilization with p-value and
95% CI.
Clinical Group Description
n
Admissions
(Pre and
Post)
Unadjusted Change Pre-utilization Versus
Postutilization Adjusted Annualized Change Postutilization
Annualized
Percent Change
in Admissions
Pre Versus Post
(Unadjusted)
p-Value Pre
Versus Post
(Unadjusted)
95% CI Pre
Versus Post
(Unadjusted)
Annualized
Change in
Admissions
a
(Postutilization)
p-Value
Annualized
Change in
Admissions
95% CI
Annualized
Change in
Admissions
Cardiovascular group codes
AMI 239 28% P=0.54 0.70–1.21 246% P=0.049 0.30–0.98
Coronary atherosclerosis and
other heart disease
337 228% P,0.01 0.56–0.92 249% P=0.04205 0.28–0.94
Nonspecific chest pain 559 14% P=0.13 0.96–1.36 232% P=0.07 0.45–1.03
Congestive heart failure 279 103% p,0.001 1.61–2.57 14% P=0.74 0.54–2.37
Respiratory group codes
Pneumonia except by TB or STD 832 16% p,0.05 1.01–1.34 14% P=0.40 0.82–1.62
COPD and bronchiectasis 912 91% p,0.001 1.68–2.18 21% P=0.39 0.79–1.84
Asthma 938 29% p,0.001 1.13–1.48 21% P=0.95 0.67–1.46
Respiratory failure insufficiency
arrest
260 64% p,0.001 1.29–2.10 26% P=0.84 0.55–1.64
Other conditions
Diabetes mellitus with
complications
462 10% P=0.33 0.90–1.33 23% P=0.93 0.51–1.92
Biliary tract disease 225 214% P=0.32 0.65–1.15 213% P=0.67 0.45–1.68
Pancreatic disorders not diabetes 525 4% P=0.68 0.87–1.25 42% P=0.30 0.73–2.79
Skin and subcutaneous skin
infections
655 ,1% P=0.96 0.84–1.17 226% P=0.24 0.45–1.22
Abdominal pain 282 15% p,0.05 1.04–1.69 218% P=0.46 0.48–1.39
Mood disorders 419 23% p,0.05 0.62–0.96 37% P=0.18 0.77–2.43
Schizophrenia and other
psychotic disorders
350 211% P=0.33 0.71–1.12 42% P=0.31 0.67–3.44
All hospitalizations 17,724 7% p,0.001 1.03–1.10 22% P=0.74 0.90–1.08
aAdjusted for trend, seasonality, influenza like cases, individual demographics, prior diagnoses of specific diseases, prior use of hypertension or cholesterol medication,
CDPS health risk score, and the implementation date of the Massachusetts Smoke-Free Workplace Law.
STD, sexually transmitted disease; TB, tuberculosis.
doi:10.1371/journal.pmed.1000375.t003
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in hospital care utilization, specifically inpatient hospital admis-
sions for acute coronary heart disease, a tobacco-related diagnosis
that is particularly sensitive to decrease in response to smoking
cessation [18,19]. Our analysis of medical claims for MassHealth
subscribers who used tobacco cessation medications paid for by
MassHealth showed a significant reduction in inpatient hospital
claims for two acute CHD diagnoses (AMI and coronary
atherosclerosis) in the postutilization period, compared to the
pre-utilization period. The findings were robust and persisted after
adjustment for potential confounding factors that included
demographics, medical comorbidities, seasonality, statewide influ-
enza rates, and the implementation date of the Massachusetts
Smoke-Free Workplace Law. We found a 46% annualized
decrease in inpatient claims for AMI and a 49% annualized
decreased in hospital claims for coronary atherosclerosis claims in
the postutilization period. No significant changes occurred in
rates of hospital admissions for other diagnoses, including four
respiratory conditions (pneumonia, asthma, COPD, and respira-
tory failure) and in seven additional diagnostic groups not
previously associated with smoking or with short-term health
improvements following smoking cessation.
Because return-on-investment (ROI) analyses have often shown
short-term increases followed by long-term decreases in health
care costs for recent quitters, nonlinear trends were evaluated for
all 15 diagnostic groups. No diagnosis group showed any
significant nonlinearity.
To date, to our knowledge, no study has linked use of the
tobacco cessation benefit with a reduction in claims for tobacco-
related diagnoses. However, several recent studies have shown
reductions in tobacco-related diagnoses following implementation
of smoke-free air laws [20–22]. Moreover, the impact of smoke-
free air laws appears to increase as a function of time in much the
same way that the risk of tobacco-related diagnoses decreases after
a smoker quits smoking [18,19]. Therefore, the longitudinal model
we used to study the health impact of the MassHealth tobacco
cessation benefit mirrors the models used to evaluate the health
effects of smoke-free air laws.
This study has several limitations. First, claims records were
used as proxies for health events. Review of clinical charts would
have yielded a more sensitive accounting of diagnoses but were
impractical given the large volume of individual subscribers.
Second, unmeasured confounding is a threat to the study’s internal
validity. Because subscribers were not randomly assigned to the
benefit and there was no concurrent control condition, it is
possible that subscribers who chose to use the tobacco benefit were
also more likely to adhere to treatment for other CHD risk factors
such as hypertension or hyperlipidemia. This behavior could
independently reduce their likelihood of hospitalization for CHD.
To partially address this issue, our model adjusted for simulta-
neous use of medications for hypertension and hyperlipidemia.
However, claims data alone cannot fully address the issue of
adherence to prescription schedules. Third, use of the tobacco
benefit is used as a proxy for stopping smoking, because smoking
status is not available in claims data; this might lead to
misclassification of benefit users who did not quit as quitters,
and would have the effect of biasing the results toward the null.
Finally, Table 2 shows differences between included and excluded
subscribers on the basis of eligibility criteria. These differences
could limit the generalizability of results to the entire population of
MassHealth subscribers.
Because of these limitations, additional studies in other states are
warranted. The authors note that initial studies showing
reductions in smoking-related diagnoses following implementation
of smoke-free laws were met with skepticism. However, subsequent
research has greatly increased confidence in the relationship
between smoke-free workplace laws and reductions in smoking-
related diagnoses, especially myocardial infarction [23]. Those
studies used a similar longitudinal model, but only research from
other states will determine whether these new results from
Massachusetts reflect a replicable pattern of hospital utilization
following the implementation of a comprehensive tobacco
treatment benefit.
It is unlikely that our findings would have reached significance
without the high utilization rate of the Massachusetts Medicaid
tobacco cessation benefit. Nearly 40% of subscribers used the
benefit in the first 2.5 y after implementation [5]. This rate was
achieved, in part, by heavy promotion of the benefit in
Massachusetts during the first 18 mo after implementation. The
Massachusetts Medicaid Program and the Massachusetts Tobacco
Cessation and Prevention Program (MTCP) formed a close
working relationship to promote the benefit. In addition, the
FDA approved varenicline as a tobacco cessation medication in
May 2006. A media campaign by varenicline’s manufacturer
promoting the product began in December 2006 and may have
increased smokers’ interest in obtaining smoking cessation
treatment.
As noted previously, this study is the second in a series of studies
regarding use the MassHealth tobacco cessation benefit. The first
study used secondary survey data from the BRFSS to show a
significant reduction in smoking prevalence for the Massachusetts
Medicaid population. This reduction coincided with the imple-
mentation of the tobacco cessation benefit [5]. The current study
has focused on reduced inpatient hospitalization claims for
tobacco-related diagnoses. Two more papers are planned for this
series. The first will focus on evaluating changes in claims for
ambulatory visits for Medicaid subscribers who used the
MassHealth tobacco cessation benefit. The second will focus on
costs and estimated cost savings. The analytic models required for
these latter studies are so substantially different from the one
presented here that it is necessary to present the material in
separate papers.
In preparing this paper, we sought to find other comparable
datasets from Medicaid agencies in other states. Little information,
if any, was readily available. While demographics may vary from
state to state, there was nothing in our results to indicate that the
health benefits from quitting smoking would be significantly
different in Massachusetts than from any other state’s Medicaid
population. However, it is still important to note that our study
was conducted in a low socioeconomic status (SES) population.
Individuals of low SES are at greater risk of a wide range of health
conditions through complex and sometimes poorly understood
interactions between physical, social, and behavioral mechanisms
[24–26]. Though we control for preexisting and comorbid health
conditions, we cannot know for sure whether unmeasured factors
or complex interactions may limit the generalizability of our
findings to other populations. Nonetheless, the results reported
here are promising. If replicated across state Medicaid programs,
these findings have important implications for reducing costly
hospitalizations and improving the health of our nation’s poorest
residents.
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Background. Smoking is the leading preventable cause of
death in the world. Globally, it is responsible for one in ten
deaths among adults. In developed countries, the death toll
is even higher—in the USA and the UK, for example, one in
five deaths are caused by cigarette smoking. In the USA
alone, where a fifth of adults smoke, smoking accounts for
more than 400,000 deaths every year; globally, smoking
causes 5 million deaths per year. On average, smokers die 14
years earlier than nonsmokers, and half of all long-term
smokers will die prematurely because of a smoking-related
disease. These diseases include lung cancer, other types of
cancer, heart disease, stroke, and lung diseases such as
chronic airway obstruction, bronchitis, and emphysema. And,
for every smoker who dies from one of these smoking-
related diseases, another 20 will develop at least one serious
disease because of their addiction to tobacco.
Why Was This Study Done? About half of US smokers try
to quit each year but most of these attempts fail. Many
experts believe that counseling and/or treatment with
tobacco cessation medications such as nicotine
replacement products help smokers to quit. In the USA,
where health care is paid for through private or state health
insurance, there is some evidence that insurance coverage of
tobacco cessation medications increases their use and
reduces smoking prevalence. However, smoking cessation
treatment is poorly covered by US health insurance
programs, largely because of uncertainty about the impact
of such coverage on health care costs. It is unknown, for
example, whether the introduction of publicly funded
tobacco cessation benefits decreases claims for treatment
for tobacco-related diseases. In this longitudinal study (a
study that follows a group of individuals over a period of
time), the researchers ask whether the adoption of
comprehensive coverage of tobacco cessation medications
by the Massachusetts Medicaid program (MassHealth) in July
2006 has affected claims for treatment for tobacco-related
diseases. During its first two and half years, more than 75,000
MassHealth subscribers used the tobacco cessation
medication benefit and smoking prevalence among
subscribers declined by approximately 10% (38.3% to 28.8%).
What Did the Researchers Do and Find? The researchers
used MassHealth claims data and a statistical method called
generalized estimating equations to compare the probability
of hospitalization prior to the use of tobacco cessation
medication benefit with the probability of hospitalization
after benefit use among MassHealth subscribers. After
adjusting for other factors that might have affected
hospitalization such as influenza outbreaks and the
implementation of the Massachusetts Smoke-Free
Workplace Law in July 2004, there was a statistically
significant annualized decline in hospital admissions for
heart attack of 46% after use of the tobacco cessation
medication benefit. That is, the calculated annual rate of
admissions for heart attacks was 46% lower after use of the
benefit than before among MassHealth beneficiaries. There
was also a 49% annualized decline in admissions for coronary
atherosclerosis, another smoking-related heart disease. There
were no significant changes in hospitalization rates for lung
diseases (including asthma, pneumonia, and chronic airway
obstruction) or for seven other diagnostic groups.
What Do These Findings Mean? These findings show
that, among MassHealth subscribers, the use of a tobacco
cessation medication benefit was followed by a significant
decrease in claims for hospitalization for heart attack and for
coronary atherosclerosis but not for other diseases. It does
not, however, show that the reduced claims for
hospitalization were associated with a reduction in
smoking because smoking cessation was not recorded by
MassHealth. Furthermore, it is possible that the people who
used the tobacco cessation medication benefit shared other
characteristics that reduced their chances of hospitalization
for heart disease. For example, people using tobacco
cessation medication might have been more likely to
adhere to prescription schedules for medications such as
statins that would also reduce their risk of heart disease.
Finally, these findings might be unique to Massachusetts, so
similar studies need to be undertaken in other states.
Nevertheless, the results of this study suggest that, for low-
income smokers, removing financial barriers to the use of
smoking cessation medications has the potential to produce
short-term decreases in the use of hospital services that will,
hopefully, outweigh the costs of comprehensive tobacco
cessation medication benefits.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000375.
N The US Centers for Disease Control and Prevention Office
on Smoking and Health has information on all aspects of
smoking and health, including advice on how to quit
N The UK National Health Service Choices Web site provides
advice about quitting smoking; more advice on quitting is
provided by Smokefree
N The American Heart Association provides information on
heart disease, including advice on how to quit smoking (in
several languages)
N Information about MassHealth is available, including
information on smoking and tobacco use prevention
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